Cellectis S.A. (CLLS) Rating Increased to Hold at Zacks Investment Research
Cellectis S.A. (NASDAQ:CLLS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Tuesday.
According to Zacks, “Cellectis SA is a gene-editing company. The company focused on developing immunotherapies based on gene edited engineered CAR-T cells. Cellectis SA is based in Paris, France. “
Several other equities analysts also recently issued reports on the stock. SunTrust Banks, Inc. reaffirmed a “hold” rating and set a $20.00 price objective on shares of Cellectis in a report on Friday, October 6th. Jefferies Group LLC reaffirmed a “buy” rating and set a $47.00 price objective on shares of Cellectis in a report on Tuesday, September 26th. Nomura decreased their price objective on shares of Cellectis from $49.00 to $43.00 and set a “buy” rating on the stock in a report on Wednesday, September 6th. Wells Fargo & Company reaffirmed an “outperform” rating and set a $40.00 price objective (up from $33.00) on shares of Cellectis in a report on Tuesday, September 5th. Finally, BidaskClub raised shares of Cellectis from a “strong sell” rating to a “sell” rating in a report on Wednesday, August 23rd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $39.00.
Shares of Cellectis (NASDAQ:CLLS) traded up 3.13% during mid-day trading on Tuesday, reaching $31.94. 354,604 shares of the company’s stock were exchanged. The company’s 50 day moving average is $28.39 and its 200 day moving average is $28.39. The stock’s market capitalization is $1.15 billion. Cellectis has a 1-year low of $16.09 and a 1-year high of $32.24.
COPYRIGHT VIOLATION NOTICE: This report was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/10/24/cellectis-s-a-clls-rating-increased-to-hold-at-zacks-investment-research.html.
Several large investors have recently bought and sold shares of the company. ARK Investment Management LLC lifted its stake in shares of Cellectis by 79.1% in the second quarter. ARK Investment Management LLC now owns 4,038 shares of the biotechnology company’s stock worth $104,000 after buying an additional 1,784 shares in the last quarter. Eqis Capital Management Inc. lifted its stake in shares of Cellectis by 27.2% in the second quarter. Eqis Capital Management Inc. now owns 10,687 shares of the biotechnology company’s stock worth $276,000 after buying an additional 2,287 shares in the last quarter. Wells Fargo & Company MN lifted its stake in shares of Cellectis by 132.1% in the second quarter. Wells Fargo & Company MN now owns 9,550 shares of the biotechnology company’s stock worth $247,000 after buying an additional 5,435 shares in the last quarter. Williams Jones & Associates LLC purchased a new position in shares of Cellectis in the second quarter worth about $244,000. Finally, Balyasny Asset Management LLC purchased a new position in shares of Cellectis in the second quarter worth about $719,000. 14.82% of the stock is currently owned by hedge funds and other institutional investors.
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cellectis S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis S.A. and related companies with MarketBeat.com's FREE daily email newsletter.